Maro Ohanian, D.O.

Peer-Reviewed Articles

1. Jabbour EJ, Short NJ, Jain N, Jammal N, Jorgensen J, Wang S, Wang X, Ohanian M, Alvarado Y, Kadia T, Sasaki K, Garris R, Garcia-Manero G, Ravandi F, Kantarjian HM. Blinatumomab Is Associated with Favorable Outcomes in Patients With B-cell Lineage Acute Lymphoblastic Leukemia and Positive Measurable Residual Disease at a Threshold of 10-4 and Higher. Am J Hematol 97(9):1135-1141, 2022. e-Pub 2022. PMID: 35713551.
2. Bazinet A, Darbaniyan F, Jabbour E, Montalban-Bravo G, Ohanian M, Chien K, Kadia T, Takahashi K, Masarova L, Short N, Alvarado Y, Yilmaz M, Ravandi F, Andreeff M, Kanagal-Shamanna R, Ganan-Gomez I, Colla S, Qiao W, Huang X, McCue D, Mirabella B, Kantarjian H, Garcia-Manero G. Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study. Lancet Haematol, 2022. e-Pub 2022. PMID: 36063832.
3. Borthakur G, Ravandi F, Patel K, Wang X, Kadia T, DiNardo C, Garcia-Manero G, Pemmaraju N, Jabour E, Takahashi K,Ohanian M, Daver N, Alvarado Y, Brandt M, Pierce S, Kantarjian H. Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients. Am J Hematol, 2022. e-Pub 2022. PMID: 36053747.
4. Senapati J, Shoukier M, Garcia-Manero G, Wang X, Patel K, Kadia T, Ravandi F, Pemmaraju N, Ohanian M, Daver N, DiNardo C, Alvarado Y, Aldrich J, Borthakur G. Activity of Decitabine as Maintenance Therapy in Core Binding Factor Acute Myeloid Leukemia. Am J Hematol 97(5):574-582, 2022. e-Pub 2022. PMID: 35150150.
5. Yilmaz M, Kantarjian H, Short NJ, Reville P, Konopleva M, Kadia T, DiNardo C, Borthakur G, Pemmaraju N, Maiti A, Jabbour E, Jain N, Issa G, Takahashi K, Sasaki K, Ohanian M, Pierce S, Tang G, Loghavi S, Patel K, Wang SA, Garcia-Manero G, Andreeff M, Ravandi F, Daver N. Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML. Blood Cancer J 12(5):77, 2022. e-Pub 2022. PMID: 35501304.
6. Ohanian M, Cancelas JA, Davenport R, Pullarkat V, Hervig T, Broome C, Marek K, Kelly M, Gul Z, Rugg N, Nestheide S, Kinne B, Szczepiorkowski Z, Kantarjian H, Pehta J, Biehl R, Yu A, Aung F, Antebi B, Fitzpatrick GM. Freeze-Dried Platelets Are a Promising Alternative in Bleeding Thrombocytopenic Patients with Hematological Malignancies. Am J Hematol 97(3):256-266, 2022. e-Pub 2021. PMID: 34748664.
7. Mill CP, Fiskus W, DiNardo CD, Birdwell C, Davis JA, Kadia TM, Takahashi K, Short N, Daver N, Ohanian M, Borthakur G, Kornblau SM, Green MR, Qi Y, Su X, Khoury JD, Bhalla KN. Effective therapy of AML with RUNX1 mutation by co-treatment with inhibitors of protein translation and BCL2. Blood 139(6):907-921, 2022. e-Pub 2021. PMID: 34601571.
8. Venugopal S, Takahashi K, Daver N, Maiti A, Borthakur G, Loghavi S, Short NJ, Ohanian M, Masarova L, Issa G, Wang X, Carlos BR, Yilmaz M, Kadia T, Andreeff M, Ravandi F, Konopleva M, Kantarjian HM, DiNardo CD. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. Blood Cancer J 12(1):10, 2022. e-Pub 2022. PMID: 35078972.
9. Abbas HA, Reville PK, Geppner A, Rausch CR, Pemmaraju N, Ohanian M, Sasaki K, Borthakur G, Daver N, DiNardo C, Bueso-Ramos C, Pierce S, Jabbour E, Garcia-Manero G, Konopleva M, Ravandi F, Kantarjian H, Kadia TM. Clinical and molecular characterization of myeloid sarcoma without medullary leukemia. Leuk Lymphoma 62(14):1-9, 2021. e-Pub 2021. PMID: 34380367.
10. Venugopal S, Maiti A, DiNardo CD, Qiao W, Ning J, Loghavi S, Daver NG, Kadia TM, Rausch CR, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Ravandi F, Kantarjian HM, Konopleva MY. Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine. Leuk Lymphoma 62(14):1-5, 2021. e-Pub 2021. PMID: 34474640.
11. Kim K, Maiti A, Loghavi S, Pourebrahim R, Kadia TM, Rausch CR, Furudate K, Daver NG, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Tang G, Ravandi F, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax. Cancer 127(20):3772-3781, 2021. e-Pub 2021. PMID: 34255353.
12. Jain N, Keating M, Thompson P, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov Z, Sasaki K, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang SA, Garg N, Wang X, Wei C, Cruz N, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda WG. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol 7(8):1213-1219, 2021. e-Pub 2021. PMID: 34110383.
13. Yilmaz M, Daver N, Borthakur G, Kadia T, DiNardo C, Kanagal-Shamanna R, Loghavi S, Oran B, Popat UR, Pierce S, Jabbour E, Short NJ, Issa G, Ohanian M, Konopleva M, Patel K, Kantarjian H, Ravandi F. FLT3 inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed Acute Myeloid Leukemia with very low FLT3 allelic burden. Am J Hematol 96(8):E275-E279, 2021. e-Pub 2021. PMID: 33891709.
14. Swaminathan M, Kantarjian HM, Levis M, Guerra V, Borthakur G, Alvarado Y, DiNardo CD, Kadia T, Garcia-Manero G, Ohanian M, Daver N, Konopleva M, Pemmaraju N, Ferrajoli A, Andreeff M, Jain N, Estrov Z, Jabbour EJ, Wierda WG, Pierce S, Pinsoy MR, Xiao L, Ravandi F, Cortes JE. A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Haematologica 106(8):2121-2130, 2021. e-Pub 2021. PMID: 33853292.
15. Pemmaraju N, Carter BZ, Bose P, Jain N, Kadia TM, Garcia-Manero G, Bueso-Ramos CE, DiNardo CD, Bledsoe S, Daver NG, Popat U, Konopleva MY, Zhou L, Pierce S, Estrov ZE, Borthakur GM, Ohanian M, Qiao W, Masarova L, Wang X, Mak PY, Cortes J, Jabbour E, Verstovsek S. Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis. Blood Adv 5(16):3163-3173, 2021. PMID: 34424319.
16. Rausch CR, DiNardo CD, Maiti A, Jammal NJ, Kadia TM, Marx KR, Borthakur G, Savoy JM, Pemmaraju N, DiPippo AJ, Daver NG, Chew SM, Sasaki K, Issa GC, Short NJ, Takahashi K, Ohanian M, Ning J, Xiao L, Alvarado Y, Kontoyiannis DP, Ravandi F, Kantarjian HM, Konopleva MY. Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia. Cancer 127(14):2489-2499, 2021. e-Pub 2021. PMID: 33793970.
17. Jabbour E, Sasaki K, Short NJ, Ravandi F, Huang X, Khoury JD, Kanagal-Shamanna R, Jorgensen J, Khouri IF, Kebriaei P, Jain N, Alvarado Y, Kadia TM, Paul S, Garcia-Manero G, Dabaja BS, Burger JA, DiNardo CD, Daver NA, Montalban-Bravo G, Yilmaz M, Ohanian M, Ferrajoli A, Jacob J, Rostykus M, Garris R, O'Brien S, Kantarjian HM. Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer 127(12):2025-2038, 2021. e-Pub 2021. PMID: 33740268.
18. Venugopal S, Maiti A, DiNardo CD, Loghavi S, Daver NG, Kadia TM, Rausch CR, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Ravandi F, Kantarjian HM, Konopleva MY. Decitabine and Venetoclax for IDH1/2-mutated Acute Myeloid Leukemia. Am J Hematol 96(5):E154-E157, 2021. e-Pub 2021. PMID: 33580980.
19. Dalle IA, Paranal R, Zarka J, Paul S, Sasaki K, Li W, Ning J, Short NJ, Ohanian M, Cortes JE, Jabbour EJ, Issa GC. Impact of luteinizing hormone suppression on hematopoietic recovery after intensive chemotherapy in patients with leukemia. Haematologica Online ahead of print(4):1097-1105, 2021. e-Pub 2021. PMID: 33297667.
20. Lachowiez CA, Loghavi S, Furudate K, Montalban-Bravo G, Maiti A, Kadia T, Daver N, Borthakur G, Pemmaraju N, Sasaki K, Alvarado Y, Yilmaz M, Short NJ, Chien K, Ohanian M, Pierce S, Patel KP, Jabbour E, Ravandi F, Kantarjian HM, Garcia-Manero G, Takahashi K, Konopleva MY, DiNardo CD. Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. Blood Adv 5(8):2173-2183, 2021. PMID: 33885753.
21. Maiti A, DiNardo CD, Wang SA, Jorgensen J, Kadia TM, Daver NG, Short NJ, Yilmaz M, Pemmaraju N, Borthakur G, Bose P, Issa GC, Ferrajoli A, Jabbour EJ, Jain N, Garcia-Manero G, Ohanian M, Takahashi K, Montalban-Bravo G, Masarova L, Burger JA, Thompson PA, Verstovsek S, Sasaki K, Andreeff M, Rausch CR, Montalbano KS, Pierce S, Qiao W, Ning J, Kantarjian HM, Konopleva MY, Ravandi F. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv 5(7):1876-1883, 2021. PMID: 33792630.
22. Maiti A, Qiao W, Sasaki K, Ravandi F, Kadia TM, Jabbour EJ, Daver NG, Borthakur G, Garcia-Manero G, Pierce SA, Montalbano KS, Pemmaraju N, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Takahashi K, Yilmaz M, Jain N, Kornblau SM, Andreeff M, Bose P, Ferrajoli A, Issa GC, Masarova L, Thompson PA, Rausch CR, Ning J, Kantarjian HM, DiNardo CD, Konopleva MY. Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality. Am J Hematol 96(3):282-291, 2021. e-Pub 2020. PMID: 33264443.
23. Reville PK, Kantarjian HM, Ravandi F, Jabbour E, DiNardo CD, Daver N, Pemmaraju N, Ohanian M, Alvarado Y, Xiao L, Alatrash G, Loghavi S, Rausch CR, Borthakur G, Konopleva M, Cortes J, Kadia TM. Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study. Blood Cancer J 11(3):60, 2021. e-Pub 2021. PMID: 33731681.
24. Alotaibi AS, Yilmaz M, Kanagal-Shamanna R, Loghavi S, Kadia TM, DiNardo CD, Borthakur G, Konopleva M, Pierce SA, Wang SA, Tang G, Guerra V, Samra B, Pemmaraju N, Jabbour E, Short NJ, Issa GC, Ohanian M, Garcia-Manero G, Bhalla KN, Patel KP, Takahashi K, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver N. Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors. Blood Cancer Discov 2(2):125-134, 2021. e-Pub 2020. PMID: 33681815.
25. Maiti A, DiNardo CD, Daver NG, Rausch CR, Ravandi F, Kadia TM, Pemmaraju N, Borthakur G, Bose P, Issa GC, Short NJ, Yilmaz M, Montalban-Bravo G, Ferrajoli A, Jabbour EJ, Jain N, Ohanian M, Takahashi K, Thompson PA, Loghavi S, Montalbano KS, Pierce S, Wierda WG, Kantarjian HM, Konopleva MY. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood Cancer J 11(2):25, 2021. e-Pub 2021. PMID: 33563904.
26. Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, Kadia TM, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, Jabbour EJ, Garcia-Manero G, Pemmaraju N, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NG. Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol 14(1):34, 2021. e-Pub 2021. PMID: 33618754.
27. Saberian C, Abdel-Wahab N, Abudayyeh A, Rafei H, Joseph J, Rondon G, Whited L, Gruschkus S, Fa'ak F, Daher M, Knape C, Safa H, Shoukier M, Suarez-Almazor ME, Marcotulli M, Ludford K, Gulbis AM, Konopleva M, Ohanian M, Ravandi F, Garcia-Manero G, Oran B, Popat UR, Mehta R, Alousi AM, Daver N, Champlin R, Diab A, Al-Atrash G. Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation. J Immunother Cancer 9(2), 2021. PMID: 33637601.
28. Issa GC, Kantarjian HM, Xiao L, Ning J, Alvarado Y, Borthakur G, Daver N, DiNardo CD, Jabbour E, Bose P, Jain N, Kadia TM, Naqvi K, Pemmaraju N, Takahashi K, Verstovsek S, Andreeff M, Kornblau SM, Estrov Z, Ferrajoli A, Garcia-Manero G, Ohanian M, Wierda WG, Ravandi F, Cortes JE. Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia 34(11):2914-2924, 2020. e-Pub 2020. PMID: 32546726.
29. Abaza Y, Kantarjian H, Alwash Y, Borthakur G, Champlin R, Kadia T, Garcia-Manero G, Daver N, Ravandi F, Verstovsek S, Burger J, Estrov Z, Ohanian M, Lim M, Pemmaraju N, Jabbour E, Cortes J. Phase I/II Study of Dasatinib in Combination with Decitabine in Patients with Accelerated or Blast Phase Chronic Myeloid Leukemia. Am J Hematol 95(11):1288-1295, 2020. e-Pub 2020. PMID: 32681739.
30. DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol 7(10):e724-e736, 2020. e-Pub 2020. PMID: 32896301.
31. Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, Kadia TM, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, Jabbour EJ, Garcia-Manero G, Pemmaraju N, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NG. Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol 13(1):132, 2020. e-Pub 2020. PMID: 33032648.
32. Navada SC, Garcia-Manero G, OdchimarReissig R, Pemmaraju N, Alvarado Y, Ohanian MN, John RB, Demakos EP, Zbyszewski PS, Maniar M, Woodman RC, Fruchtman SM, Silverman LR. Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study. Leuk Res 94:106369, 2020. e-Pub 2020. PMID: 32442785.
33. Samra B, Richard-Carpentier G, Kadia TM, Ravandi F, Daver N, DiNardo CD, Issa GC, Bose P, Konopleva MY, Yilmaz M, Ohanian M, Borthakur G, Garcia-Manero G, Pierce S, Cortes JE, Kantarjian H, Short NJ. Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype. Blood Cancer J 10(5):47, 2020. e-Pub 2020. PMID: 32366832.
34. Richard-Carpentier G, Jabbour E, Short NJ, Rausch CR, Savoy JM, Bose P, Yilmaz M, Jain N, Borthakur G, Ohanian M, Alvarado Y, Rytting M, Kebriaei P, Konopleva M, Kantarjian H, Ravandi F. Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 20(4):212-218, 2020. e-Pub 2019. PMID: 32035785.
35. Lachowiez CA, Loghavi S, Kadia TM, Daver N, Borthakur G, Pemmaraju N, Naqvi K, Alvarado Y, Yilmaz M, Short N, Ohanian M, Pierce SR, Patel KP, Qiao W, Ning J, Sasaki K, Takahashi K, Jabbour E, Andreeff M, Ravandi F, Kantarjian HM, Konopleva M, DiNardo CD. Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. Blood Adv 4(7):1311-1320, 2020. PMID: 32251497.
36. Abou Dalle I, Kantarjian H, Burger J, Estrov Z, Ohanian M, Verstovsek S, Ravandi F, Borthakur G, Garcia-Manero G, Jabbour E, Cortes J. Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States. Cancer Med 8(15):6559-6565, 2019. e-Pub 2019. PMID: 31502383.
37. Jain N, Keating MJ, Thompson PA, Ferrajoli A, Burger JA, Borthakur GM, Takahashi K, Estrov ZE, Fowler NH, Kadia TM, Konopleva MY, Alvarado Y, Yilmaz M, DiNardo CD, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen JL, Wang SA, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian HM, Gandhi V, Wierda WG. Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL). Blood 134(Supplement_1):34, 2019. PMID: 31724006.
38. Ohanian M, Tung C, V Abruzzo L. Orbital extramedullary leukaemia is not a rare entity - response to Paydas. Br J Haematol 186(3):e4-e6, 2019. e-Pub 2019. PMID: 30873605.
39. Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med 380(22):2095-2103, 2019. PMID: 31141631.
40. Boddu P, Thakral B, Alhuraiji A, Pemmaraju N, Kadia T, Ohanian M, Ravandi F, Jabbour E, Wierda W, Khoury JD, Jain N. Distinguishing thymoma from T-lymphoblastic leukaemia/lymphoma: a case-based evaluation. J Clin Pathol 72(3):251-257, 2019. e-Pub 2018. PMID: 30467242.
41. Burger JA, Sivina M, Jain N, Kim E, Kadia T, Estrov Z, Nogueras-Gonzalez GM, Huang X, Jorgensen J, Li J, Cheng M, Clow F, Ohanian M, Andreeff M, Mathew T, Thompson P, Kantarjian H, O'Brien S, Wierda WG, Ferrajoli A, Keating MJ. Randomized trial of ibrutinib versus ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood 133(10):1011-1019, 2019. e-Pub 2018. PMID: 30530801.
42. Maiti A, Naqvi K, Kadia TM, Borthakur G, Takahashi K, Bose P, Daver NG, Patel A, Alvarado Y, Ohanian M, DiNardo CD, Cortes JE, Jabbour EJ, Garcia-Manero G, Kantarjian HM, Ravandi F. Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 19(3):142-148.e1, 2019. e-Pub 2018. PMID: 30635233.
43. Ohanian M, Rozovski U, Kanagal-Shamanna R, Abruzzo LV, Loghavi S, Kadia T, Futreal A, Bhalla K, Zuo Z, Huh YO, Post SM, Ruvolo P, Garcia-Manero G, Andreeff M, Kornblau S, Borthakur G, Hu P, Medeiros LJ, Takahashi K, Hornbaker MJ, Zhang J, Nogueras-González GM, Huang X, Verstovsek S, Estrov Z, Pierce S, Ravandi F, Kantarjian HM, Bueso-Ramos CE, Cortes JE. MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leuk Lymphoma 60(1):1-12, 2019. e-Pub 2018. PMID: 29741984.
44. Short NJ, Kantarjian HM, Loghavi S, Huang X, Qiao W, Borthakur G, Kadia TM, Daver N, Ohanian M, Dinardo CD, Estrov Z, Kanagal-Shamanna R, Maiti A, Benton CB, Bose P, Alvarado Y, Jabbour E, Kornblau SM, Pemmaraju N, Jain N, Gasior Y, Richie MA, Pierce S, Cortes J, Konopleva M, Garcia-Manero G, Ravandi F. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematol 6(1):e29-e37, 2019. e-Pub 2018. PMID: 30545576.
45. Yalniz FF, Daver N, Rezvani K, Kornblau S, Ohanian M, Borthakur G, DiNardo CD, Konopleva M, Burger J, Gasior Y, Pierce S, Kantarjian H, Garcia-Manero G. A Pilot Trial of Lirilumab With or Without Azacitidine for Patients With Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk 18(10):658-663.e2, 2018. e-Pub 2018. PMID: 30001986.
46. Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, Ravandi-Kashani F, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, Kadia TM, DiNardo CD, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver N. A phase II study of ruxolitinib in combination with azacytidine in patients with myelofibrosis. Blood 132(16):1664-1674, 2018. e-Pub 2018. PMID: 30185431.
47. Ohanian M, Garcia-Manero G, Levis M, Jabbour E, Daver N, Borthakur G, Kadia T, Pierce S, Burger J, Richie MA, Patel K, Andreeff M, Estrov Z, Cortes J, Kantarjian H, Ravandi F. Sorafenib Combined with 5-azacytidine (AZA) in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia (AML). Am J Hematol 93(9):1136-1141, 2018. e-Pub 2018. PMID: 30028037.
48. Lacourt TE, Kavelaars A, Ohanian M, Shah ND, Shelburne SA, Futreal A, Kontoyiannis DP, Heijnen CJ. Patient-reported fatigue prior to treatment is prognostic of survival in patients with acute myeloid leukemia. Oncotarget 9(58):31244-31252, 2018. e-Pub 2018. PMID: 30131851.
49. Ohanian M, Tari Ashizawa A, Garcia-Manero G, Pemmaraju N, Kadia T, Jabbour E, Ravandi F, Borthakur G, Andreeff M, Konopleva M, Lim M, Pierce S, O'Brien S, Alvarado Y, Verstovsek S, Wierda W, Kantarjian H, Cortes J. Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial. Lancet Haematol 5(4):e136-e146, 2018. e-Pub 2018. PMID: 29550383.
50. Ohanian M, Ashizawa AT, Garcia-Manero G, Pemmaraju N, Kadia T, Jabbour E, Ravandi F, Borthakur G, Andreeff M, Konopleva M, Lim M, Pierce S, O'Brien S, Alvarado Y, Verstovsek S, Wierda W, Kantarjian H, Cortes J. Phase I study of BP1001 (liposomal Grb2 antisense oligodeoxynucleotide) in patients with refractory or relapsed hematologic malignancies, 2018. e-Pub 2018.
51. Ohanian M, Pemmaraju N, Rozovski U, Alattar ML, Estrov Z, Kundra V, Tung C, Ravandi F, Manning J, Abruzzo LV. Ocular extramedullary myeloid leukaemia. Br J Haematol 180(5):738-740, 2018. e-Pub 2016. PMID: 27879987.
52. Ragon BK, Daver N, Garcia-Manero G, Ravandi F, Cortes J, Kadia T, Oran B, Ohanian M, Ferrajoli A, Pemmaraju N, Kantarjian HM, Borthakur G. Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia. Am J Hematol 92(9):845-850, 2017. e-Pub 2017. PMID: 28494506.
53. Boddu PC, Kantarjian HM, Ravandi F, Garcia-Manero G, Verstovsek S, Jabbour EJ, Takahashi K, Bhalla K, Konopleva M, DiNardo CD, Ohanian M, Pemmaraju N, Jain N, Pierce S, Wierda WG, Cortes JE, Kadia TM. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. Cancer 123(16):3050-3060, 2017. e-Pub 2017. PMID: 28387922.
54. Pinnix CC, Chi L, Jabbour EJ, Milgrom SA, Smith GL, Daver N, Garg N, Cykowski MD, Fuller G, Cachia D, Kamiya-Matsuoka C, Woodman K, Dinardo C, Jain N, Kadia TM, Pemmaraju N, Ohanian M, Konopleva M, Kantarjian HM, Dabaja BS. Dorsal column myelopathy after intrathecal chemotherapy for leukemia. Am J Hematol 92(2):155-160, 2017. PMID: 27874212.
55. Tamamyan G, Kadia T, Ravandi F, Borthakur G, Cortes J, Jabbour E, Daver N, Ohanian M, Kantarjian H, Konopleva M. Frontline treatment of acute myeloid leukemia in adults. Crit Rev Oncol Hematol 110:20-34, 2017. e-Pub 2016. PMID: 28109402.
56. Huh YO, Tang G, Talwalkar SS, Khoury JD, Ohanian M, Bueso-Ramos CE, Abruzzo LV. Double minute chromosomes in acute myeloid leukemia, myelodysplastic syndromes, and chronic myelomonocytic leukemia are associated with micronuclei, MYC or MLL amplification, and complex karyotype. Cancer Genet 209(7-8):313-20, 2016. e-Pub 2016. PMID: 27318442.
57. Ohanian M, Bueso-Ramos C, Ok CY, Lin P, Patel K, Alattar ML, Khoury JD, Rozovski U, Estrov Z, Huh YO, Cortes J, Abruzzo LV. Acute Myeloid Leukemia with MYC Rearrangement and JAK2 V617F Mutation. Cancer Genet 208(11):571-4, 2015. e-Pub 2015. PMID: 26382622.
58. Rozovski U, Ohanian M, Ravandi F, Garcia-Manero G, Faderl S, Pierce S, Cortes J, Estrov Z. Incidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia. Leuk Lymphoma 56(5):1-6, 2015. e-Pub 2014. PMID: 25110819.
59. Ohanian M, Rozovski U, Ravandi F, Garcia-Manero G, Jabbour E, Kantarjian HM, Estrov Z. Very high levels of lactate dehydrogenase at diagnosis predict central nervous system relapse in acute promyelocytic leukaemia. Br J Haematol 169(4):595-7, 2015. e-Pub 2014. PMID: 25413673.
60. Ohanian M, Kantarjian H, Guy D, Thomas D, Jabbour E, O'Brien S. Inotuzumab ozogamicin in B-cell acute lymphoblastic leukemias and non-Hodgkin's lymphomas. Expert Opin Biol Ther 15(4):601-11, 2015. PMID: 25775418.
61. Ohanian M, Huang RS, Yakoushina TV, Estrov Z, Juneja H, Chen L, Idowu M, Abruzzo LV. Isolated Mesenteric CD20-positive Myeloid Sarcoma. Clin Lymphoma Myeloma Leuk 14(6):e217-20, 2014. e-Pub 2014. PMID: 25131853.
62. Rozovski U, Li P, Harris D, Ohanian M, Kantarjian H, Estrov Z. Interleukin-7 receptor-α gene mutations are not detected in adult T-cell acute lymphoblastic leukemia. Cancer Med 3(3):550-554, 2014. e-Pub 2014. PMID: 24678068.
63. Ohanian M, Kantarjian HM, Quintas-Cardama A, Jabbour E, Abruzzo L, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Champlin R, Pierce S, Alattar ML, Trinh LX, Luthra R, Ferrajoli A, Kadia T, O'Brien S, Cortes JE. Tyrosine Kinase Inhibitors as Initial Therapy for Patients with Chronic Myeloid Leukemia in Accelerated Phase. Clin Lymphoma Myeloma Leuk 14(2):155-162.e1, 2014. e-Pub 2013. PMID: 24332214.
64. Ikoma N, Anderson CL, Ohanian M, Juneja HS, MacFadyen BV, Shah SK, Bajwa KS. Portal vein thrombosis after laparoscopic cholecystectomy. JSLS 18(1):125-7, 2014. PMID: 24680155.
65. Ohanian M, Idowu M, Castillo B, Liu H, Nedelcu E. Diagnosis with Hemoglobin SC Disease at Age 52 After Acute Stroke and Cardiac Arrest. J Hematol 2(1), 2014.
66. Ohanian M, Faderl S, Ravandi F, Pemmaraju N, Garcia-Manero G, Cortes J, Estrov Z. Is acute myeloid leukemia a liquid tumor?. Int J Cancer 133(3):534-43, 2013. e-Pub 2013. PMID: 23280377.
67. Ghanem H, Kantarjian H, Ohanian M, Jabbour E. The role of clofarabine in acute myeloid leukemia. Leuk Lymphoma 54(4):688-98, 2013. e-Pub 2012. PMID: 22957815.
68. Ohanian M, Borthakur G, Quintas-Cardama A, Mathisen M, Cortés JE, Estrov Z, Pemmaraju N. Ocular granulocytic sarcoma: a case report and literature review of ocular extramedullary acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 13(1):93-6, 2013. e-Pub 2012. PMID: 23017332.
69. Ohanian M, Leventaki V, Verstovsek S, Estrov Z, Lin P, Yin C, Kantarjian H, Huh Y, Ravandi F. Acute lymphoblastic leukemia arising in post-polycythemic myelofibrosis: a rare entity. Leuk Lymphoma 53(9):1839-41, 2012. e-Pub 2012. PMID: 22303899.
70. Ohanian M, Cortes J, Kantarjian H, Jabbour E. Tyrosine kinase inhibitors in acute and chronic leukemias. Expert Opin Pharmacother 13(7):927-38, 2012. PMID: 22519766.
71. Tanaka MF, Kantarjian H, Cortes J, Ohanian M, Jabbour E. Treatment options for chronic myeloid leukemia. Expert Opin Pharmacother 13(6):815-28, 2012. e-Pub 2012. PMID: 22429140.
72. Ohanian M, Alaly J, Samuel S, Cable C, Halka K. Leptomeningeal myelomatosis in previously treated high-risk kappa light chain multiple myeloma. Blood and Lymphatic Cancer: Targets and Therapy 1(1):9-18, 2011.
73. Ohanian M, Cable C, Halka K. Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome. Clin Pharmacol 3:5-12, 2011. e-Pub 2011. PMID: 22287852.
74. Ohanian M, Cable C, Halka K. Reduced dose maintenance eculizumab in atypical hemolytic uremic syndrome (aHUS): an update on a previous case report. Clin Pharmacol 3:45-50, 2011. e-Pub 2011. PMID: 22287856.
75. Bennett DD, Ohanian M, Cable CT. Rituximab in severe skin diseases: target, disease, and dose. Clin Pharmacol 2:135-41, 2010. e-Pub 2010. PMID: 22291497.
76. Sasaki K, Kantarjian H, Wierda W, Ravandi F, Daver N, Burger J, DiNardo CD, Jain N, Short NJ, Estrov Z, Konopleva M, Ohanian M, Garcia-Manero G, Kadia T, Alvarado Y, Yilmaz M, Pierce S, Garris R, Cortes J, O'Brien S, Ingram A, Jabbour E. Phase 2 Study of Hyper-CMAD with Liposomal Vincristine for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia. Am J Hematol. e-Pub 2020. PMID: 32170867.
77. Ohanian M, Telouk P, Kornblau S, Albarede F, Ruvolo P, Tidwell RSS, Plesa A, Kanagal-Shamanna R, Matera EL, Cortes J, Carson A, Dumontet C. A heavy metal baseline score predicts outcome in AML. Am J Hematol. e-Pub 2020. PMID: 31944361.
78. Ohanian M, Kantarjian HM, Shoukier M, Dellasala S, Musaelyan A, Nogueras Gonzalez GM, Jabbour E, Abruzzo L, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Tamamyan G, Champlin R, Pierce S, Ferrajoli A, Kadia T, Cortes JE. The Clinical Impact of Time to Response in De Novo Accelerated-Phase Chronic Myeloid Leukemia. Am J Hematol. e-Pub 2020. PMID: 32557828.
79. Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur G, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Kadia TM, Takahashi K, Yilmaz M, Jain N, Kornblau S, Montalban Bravo G, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabbour EJ, Masarova L, Thompson PA, Wang S, Konoplev S, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica. e-Pub 2020. PMID: 32499238.
80. Kadia TM, Reville PK, Wang X, Rausch CR, Borthakur G, Pemmaraju N, Daver NG, DiNardo CD, Sasaki K, Issa GC, Ohanian M, Montalban-Bravo G, Short NJ, Jain N, Ferrajoli A, Bhalla KN, Jabbour E, Takahashi K, Malla R, Quagliato K, Kanagal-Shamanna R, Popat UR, Andreeff M, Garcia-Manero G, Konopleva MY, Ravandi F, Kantarjian HM. Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. J Clin Oncol:JCO2102823. e-Pub 2022. PMID: 35704787.

Abstracts

1. Ohanian M, Martha L. Arellano, Moshe Y. Levy, Kristen O'Dwyer, Hani Babiker, Daruka Mahadevan, Hongying Zhang, Nasrin Rastgoo, Yuying Jin, Jotin Marango, Stephen B Howell, William G Rice, Rafael Bejar. A Phase 1a/b Dose Escalation Study of the MYC Repressor Apto-253 in Patients with Relapsed or Refractory AML or High-Risk MDS. Blood 138(Suppl 1), 2021.
2. Jain N, Keating MJ, Thompson PA, Ferrajoli A, Burger JA, Borthakur GM, Takahashi K, Estrov Z, Fowler NH, Kadia TM, Konopleva MY, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen JL, Wang SA, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian HM, Gandhi V, Wierda WG. Combined ibrutinib and venetoclax for first-line treatment for patients with chronic lymphocytic leukemia (CLL). Blood 134(Suppl 1):abstr 34, 2019.
3. Borthakur G, Cortes JE, Ravandi F, Garcia-Manero G, Kadia TM, Jabbour E, Patel K, Issa GC, Daver NG, Ohanian MN, Brandt M, Kantarjian HM. Fludarabine, cytarabine, G-CSF and gemtuzumab ozogamicin (FLAG-GO) regimen in better molecular response and relapse-free survival in core binding factor acute myeloid leukemia than FLAG and idarubicin (FLAG-Ida). Blood 134(Suppl 1):abstr 290, 2019.
4. Jain N, Keating MJ, Thompson PA, Burger JA, Ferrajoli A, Estrov E, Borthakur GM, Takahashi K, Bose P, Fowler NH, Kadia TM, Daver NG, Konopleva MY, Alvarado Y, Yilmaz M, DiNardo CD, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen JL, Wang SA, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian HM, Gandhi V, Wierda WG. Combined ibrutinib and venetoclax in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Blood 134(Suppl 1):abstr 359, 2019.
5. Pemmaraju N, Carter BZ, Kantarjian HM, Cortes JE, Bose P, Kadia TM, Garcia-Manero G, Bueso-Ramos CE, DiNardo CD, Bledsoe S, Daver NG, Popat U, Konopleva MY, Ohanian MN, Pierce SA, Zhou L, Estrov ZE, Borthakur GM, Mak PY, Jain N, Jabbour EJ, Verstovsek S. Final results of phase 2 clinical trial of LCL161, a novel oral SMAC mimetic/IAP antagonist, for patients with intermediate to high risk myelofibrosis. Blood 134(Suppl 1):abstr 555, 2019.
6. Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur GM, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Benton CB, Kadia TM, Takahashi K, Yilmaz M, Jain N, Kornblau SM, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabbour E, Masarova L, Rytting ME, Thompson PA, Wang SA, Konoplev S, Chen Z, Goswami M, Maduike R, Guerrero JA, Zhang Q, Cavazos A, Ma H, Bivins CA, Wade A, Adewale SL, Tse S, Thomas R, Vaughan K, Pierce SA, Ning J, Qiao W, Welch JS, Patel KP, Kantarjian HM, Konopleva MY, DiNardo CD. Outcomes in molecular subgroups and resistance patterns with ten-day decitabine and venetoclax (DEC10-VEN) in acute myeloid leukemia. Blood 134(Suppl 1):abstr 645, 2019.
7. Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur GM, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Benton CB, Kadia TM, Takahashi K, Yilmaz ME, Jain N, Kornblau SM, Montalban Bravo G, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabbour E, Masarova L, Rytting ME, Thompson PA, Wang SA, Konoplev S, Chen Z, Goswami M, Maduike R, Guerrero JA, Zhang Q, Cavazos A, Ma H, Bivins CA, Wade A, Adewale SL, Tse S, Thomas R, Vaughan K, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian HM, Konopleva MY, DiNardo CD. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent with venetoclax regimens. Blood 134(Suppl 1):abstr 738, 2019.
8. Richard-Carpentier G, Kantarjian HM, Jorgensen JL, Wang SA, Khoury JD, Ravandi F, Short NJ, Khouri R, Takahashi K, Ohanian M, Borthakur GM, Konopleva MY, Daver NG, Estrov ZE, Alvarado Y, Jain N, Kadia TM, Garcia-Manero G, Velasquez M, Nasnas P, O'Brien S, Jabbour E. Phase II study of blinatumomab in patients with B-cell acute lymphocytic leukemia (B-ALL) with positive measurable residual disease (MRD). Blood 134(Suppl 1):abstr 1299, 2019.
9. Masarova L, Verstovsek S, Bose P, Pemmaraju N, Cortes JE, Jabbour E, Ohanian M, Zhou L, Pierce SA, Gergis R, Borthakur GM, Kadia TM, DiNardo CD, Ravandi F, Konopleva MY, Naqvi K, Sasaki K, Estrov ZE, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver NG. Phase 2 study of ruxolitinib (RUX) in combination with 5-azacitidine (AZA) in patients (pts) with myelofibrosis. Blood 134(Suppl 1):abstr 1656, 2019.
10. Richard-Carpentier G, Kantarjian HM, Tang G, Yin C, Khoury JD, Issa GC, Jain N, Ravandi F, Short NJ, DiNardo CD, Takahashi K, Ohanian M, Borthakur GM, Konopleva MY, Daver NG, Estrov ZE, Alvarado Y, Ferrajoli A, Kadia TM, Garcia-Manero G, Verstovsek S, Garris R, Cortes JE, O'Brien S, Jabbour E. Characteristics and clinical outcomes of patients with acute lymphoblastic leukemia with KMT2A (MLL) rearrangementapproach. Blood 134(Suppl 1):abstr 2582, 2019.
11. Maiti A, DiNardo CD, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur GM, Naqvi K, Ohanian MN, Short NJ, Alvarado Y, Benton CB, Kadia TM, Takahashi K, Yilmaz ME, Jain N, Kornblau SM, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabbour E, Masarova L, Rytting ME, Thompson PA, Wang SA, Konoplev S, Chen Z, Goswami M, Maduike R, Guerrero JA, Zhang Q, Cavazos A, Ma H, Bivins CA, Wade A, Adewale SL, Tse S, Thomas R, Vaughan K, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian H, Konopleva MY. Ten-day decitabine with venetoclax (DEC10-VEN) in acute myeloid leukemia: updated results of a phase II trial. Blood 134(Suppl 1):abstr 2637, 2019.
12. Ramos JM, Kadia TM, Montalban-Bravo G, Benton CB, Faderl S, Sasaki K, Naqvi K, Cortes JE, Daver NG, DiNardo CD, Jabbour E, Borthakur GM, Al Azzawi H, Pemmaraju N, Konopleva MY, Pierce SA, Jain N, Ohanian M, Garcia-Manero G, Andreeff M, Kantarjian HM, Ravandi F, Alvarado Y. Liposomal cytarabine and daunorubicin (CPX-351) in combination with gemtuzumab ozogamicin (GO) in relapsed refractory (R/R) patients with acute myeloid leukemia (AML) and post- hypomethylating agent (post-HMA) failure high-risk myelodysplastic syndrome (HR-MDS). Blood 134(Suppl 1):abstr 2642, 2019.
13. Samra B, Richard-Carpentier G, Ravandi F, Kadia TM, Guerra VA, Daver NG, DiNardo CD, Issa GC, Bose P, Yilmaz M, Ohanian M, Borthakur GM, Garcia-Manero G, Pierce SA, Cortes JE, Kantarjian HM, Short NJ. Characteristics and outcomes of therapy-related versus de novo acute myeloid leukemia with normal karyotype. Blood 134(Suppl 1):abstr 3834, 2019.
14. Guerra VA, Kantarjian HM, Cortes JE, Garcia-Manero G, Masarova L, Pemmaraju N, Jabbour E, Kadia TM, DiNardo CD, Zhou L, Pierce SA, Borthakur GM, Wierda WG, Ferrajoli A, Sasaki K, Takahashi K, Naqvi K, Alvarado Y, Ohanian MN, Jain N, Bose P, Ravandi F, Konopleva MY, Estrov ZE, Verstovsek S, Daver NG. A phase II trial of azacitidine (AZA) in combination with ruxolitinib (RUX) in myelodysplastic syndrome/myeloproliferative neoplasms (MDS/MPNs). Blood 134(Suppl 1):abstr 4237, 2019.
15. Borthakur G, Cortes JE, Garcia-Manero G, Patel K, Ravandi F, Kadia TM, Pemmaraju N, Daver NG, Yilmaz M, Estrov Z, Ohanian M, Maduike R, Kantarjian HM. Addition of gemtuzumab ozogamicin (GO) to fludarabine, cytarabine and G-CSF (FLAG) based induction regimen results in better early molecular response and relapse free survival compared to idarubicin (FLAG-Ida) in newly diagnosed core binding factor leukemia. Blood 132(Suppl 1):(#3993), 2018.
16. Masarova L, Verstovsek S, Cortes JE, Pemmaraju N, Bose P, Ohanian M, Zhou L, Pierce SA, Gergis R, Borthakur G, Estrov ZE, Garcia-Manero G, Kantarjian HM, Daver NG. Updated results of phase 2 study of ruxolitinib in combination with 5-azacitidine in patients with myelofibrosis. Blood 132(Suppl 1):(#352), 2018.
17. Aboudalle I, Kantarjian HM, Short NJ, Khouri M, Takahashi K, Ohanian M, Borthakur G, Konopleva MY, Daver NG, Estrov ZE, Alvarado Y, Jain N, Ravandi F, Garcia-Manero G, Velasquez M, Nasnas P, O'Brien SM, Jabbour EJ. Phase II study of blinatumomab in patients with B-cell lineage acute lymphocytic leukemia with positive minimal/measurable residual disease. Blood 132(Suppl 1):(#5212), 2018.
18. Rausch CR, Paul S, Kantarjian HM, Ravandi F, Short NJ, Sasaki K, Khouri M, Jacob J, Montalbano KS, Thompson PA, Jain N, Yilmaz M, Naqvi K, Ohanian M, Nasnas P, Estrov ZE, O'Brien SM, Jabbour EJ. Utility of leucovorin rescue in patients with acute lymphoblastic leukemia (ALL) treated with the mini-hypercvd regimen. Blood 132(Suppl 1):(#1417), 2018.
19. Aboudalle I, Kantarjian HM, Ohanian M, Alvarado Y, Jabbour EJ, Garcia-Manero G, Naqvi K, Wierda WG, Daver NG, Burger JA, Konopleva MY, Takahashi K, Andreeff M, Pemmaraju N, Ferrajoli A, Borthakur G, Kadia TM, Ravandi F, Cortes JE. Phase I-II study of crenolanib combined with standard salvage chemotherapy and crenolanib combined with 5-azacitidine in acute myeloid leukemia patients with FLT3 activating mutations. Blood 132(Suppl 1):(#2715), 2018.
20. Garcia-Manero G, Sasaki K, Montalban-Bravo G, Bodden KR, Bose P, Alvarado Y, Daver NG, Borthakur G, Ravandi F, Takahashi K, Cortes JE, Jabbour EJ, Naqvi K, DiNardo CD, Benton CB, Pemmaraju N, Kadia TM, Ohanian M, Pierce SA, Kantarjian HM. Final report of a phase II study of guadecitabine (SGI-110) in patients (pts) with previously untreated myelodysplastic syndrome (MDS). Blood 132(Suppl 1):(#232), 2018.
21. Jain N, Keating MJ, Thompson PA, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia TM, Konopleva MY, Alvarado Y, Yilmaz M, DiNardo CD, Bose P, Ohanian M, Pemmaraju N, Jabbour EJ, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgenson JL, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian HM, Gandhi V, Wierda WG. Combined ibrutinib and venetoclax in patients with treatment-naive high-risk chronic lymphocytic leukemia (CLL). Blood 132(Suppl 1):(#696), 2018.
22. Short NJ, Kantarjian HM, Loghavi S, Huang X, Qiao W, Borthakur G, Kadia TM, Daver NG, Ohanian M, DiNardo CD, Estrov ZE, Kanagal-Shamanna R, Maiti A, Benton CB, Bose P, Alvarado Y, Jabbour EJ, Kornblau SM, Pemmaraju N, Jain N, Gasior Y, Richie MA, Pierce S, Cortes JE, Konopleva MY, Garcia-Manero G, Ravandi F. Five-day versus ten-day schedules of decitabine in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase II study. Blood 132(Suppl 1):(#84), 2018.
23. Maiti A, DiNardo CD, Cortes JE, Borthakur G, Pemmaraju N, Benton CB, Kadia TM, Takahashi K, Naqvi K, Ravandi F, Alvarado Y, Short NJ, Daver NG, Sasaki K, Ohanian MN, Garcia-Manero G, Thompson PA, Kornblau SM, Masarova L, Jain N, Jabbour EJ, Andreeff M, Maduike R, Guerrero JA, Zhang Q, Cavazos A, Ma H, Rausch CR, Bivins CA, Vaughan K, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian HM, Konopleva MY. Interim analysis of phase II study of venetoclax with 10-day decitabine (DEC10-VEN) in acute myeloid leukemia and myelodysplastic syndrome. Blood 132(Suppl 1):(#286), 2018.
24. Rausch CR, Paul S, Montalban Bravo G, Jabbour EJ, Daver NG, Alvarado Y, DiNardo CD, Ravandi F, Borthakur G, Bose P, Pemmaraju N, Naqvi K, Kornblau SM, Cortes JE, Kadia TM, Konopleva MY, Ohanian M, Pierce SA, Gasior Y, Benton CB, Jain N, Takahashi K, Masarova L, Andreeff M, Estrov ZE, Kantarjian HM, Garcia-Manero G. Pattern of immune-mediated toxicities in patients with myelodysplastic syndrome (MDS) treated with nivolumab and ipilimumab. Blood 132(Suppl 1):(#4367), 2018.
25. Navada SC, Garcia-Manero G, Atallah EL, Rajeh MN, Shammo JM, Griffiths EA, Khaled SK, Dakhil SR, Young DE, Odchimar-Reissig R, Pemmaraju N, Alvarado Y, Ohanian M, John RB, Zbyszewski PS, Maniar M, Petrone ME, Fruchtman SM, Silverman LR. Phase 2 expansion study of oral rigosertib combined with azacitidine (AZA) in patients (pts) with higher-risk (HR) myelodysplastic syndromes (MDS): efficacy and safety results in HMA treatment naive & relapsed (Rel)/refractory (ref) patients. Blood 132(Suppl 1):(#230), 2018.
26. Pemmaraju N, Carter BZ, Kantarjian HM, Cortes JE, Kadia TM, Garcia-Manero G, DiNardo CD, Bose P, Daver NG, Konopleva MY, Ohanian MN, Pierce SA, Zhou L, Estrov ZE, Borthakur G, Salinas K, Mak PY, Jain N, Jabbour EJ, Verstovsek S. LCL161, an oral smac mimetic/IAP antagonist for patients with myelofibrosis (MF): novel translational findings among long-term responders in a phase 2 clinical trial. Blood 132(Suppl 1):(#687), 2018.
27. Ohanian MN, Lin TL, Ritchie EK, Craig M, Agrawal A, Halka KG, Karur V, Pemmaraju N, Borthakur G, Aminov S, Lim M, Pierce SA, Sacarakis N, Minor S, Ashizawa AT, Hahne W, Kantarjian HM, Cortes JE, Roboz GJ. Interim safety and efficacy of lower intensity induction therapy with intravenous prexigebersen (BP1001) in patients with untreated acute myeloid leukemia (AML). Blood 132(Suppl 1):(#1387), 2018.
28. Burger JA, Sivinia M, Ferrajoli A, Jain N, Kim E, Kadia T, Estrov Z, Gonzalez GN, Huan X, Ohanian M, Andreeff M, Thomas M, Alexander-Williams L, Kantarjian HM, O'Brien SM, Wierda W, Keating MJ. Randomized trial of Ibrutinib versus Ibrutinib plus Rituximab (Ib+R) in patients with chronic lymphocytic leukemia (CLL). Blood 130(25):(#427), 2017.
29. Jain N, Thompson PA, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Bose P, Estrov Z, Jabbour E, Konopleva M, Alvarado Y, Kadia T, Yilmaz M, DiNardo CD, Ohanian M, Cortes JE, Kanagal-Shamanna R, Patel K, Garg N, Wang X, Fru N, Cruz N, Gandhi V, Plunkett W, Kantarjian HM, Keating MJ, Wierda WG. Combined venetoclax and ibrutinib for patients with prviously treated high-risk CLL, and relapsed/refractory CLL: A phase II trial. Blood 130(25):(#429), 2017.
30. Swaminathan M, Kantarjian HM, Daver N, Borthakur G, Ohanian M, Kadia T, DiNardo CD, Jain N, Estrov Z, Ferrajoli A, Garcia-Manero G, Konopleva M, Andreeff M, Pemmaraju N, Jabbour EJ, Wierda WG, Ravandi F, Pinsoy MR, Cortes JE. The combination of quizartinib with azacitidine or low dose cytarabine is highly active in patients (Pts) with FLT3-ITD mutated myeloid leukemias: interim report of a phase I/II trial. Blood 130(25):(#723), 2017.
31. Borthakur G, Kantarjian HM, DiNardo CD, Daver N, Jabbour EJ, Kadia T, Garcia-Manero G, Ravandi F, Pemmaraju N, Konopleva M, Ohanian M, Wierda WG, Jain N, Xiao L-C, Mukherjee P, Brandt M, Cortes JE. Phase II study of CPX-351 (cytarabine: daunorubicin) liposome injection in patients (pts) with newly diagnosed acute myeloid leukemia (AML) at high risk for induction mortality. Blood 130(25):(#892), 2017.
32. Rausch CR, DiNardo CD, Kadia T, Takahashi K, Jain N, Benton CB, Thompson PA, Ohanian M, Covert W, Mace M, Marx K, Pemmaraju N, Daver N, Jabbour EJ, Cortes JE, Garcia-Manero G, Ravandi F, Konopleva M, Kantarjian HM. Results of off-label venetoclax use in combination with low-intensity chemotherapy in patients with relapsed and refractory myeloid malignancies. Blood 130(25):(#1356), 2017.
33. Kebriaei P, Huls H, Neel SL, Olivares S, Orozco AF, Su S, Maiti SN, Smith A, De Groot E, Kantarjian HM, Ohanian M, Rezvani K, Shpall E, Champlin RE, Cooper LJN, Singh H. Shortening the time to manufacture CAR+ T cells with Sleeping Beauty system supports T-cell engraftment and anti-tumor effects in patients with refractory CD19+ tumors. Blood 130(25):(#2060), 2017.
34. Short NJ, Kantarjian HM, Ravandi F, Huang X, Jain N, Daver N, Thomas DA, Pemmaraju N, Khouri R, Khoury JD, Jorgensen JL, Alvarado Y, Sasaki K, Konopleva M, Garcia-Manero G, Kadia T, Cortes JE, Benton CB, Borthakur G, Burger JA, Ohanian M, Wierda WG, Estrov Z, Kornblau S, DiNardo CD, Ferrajoli A, Jacob J, Manzoor A, Garris R, O'Brien SM, Jabbour EJ. A phase I/II study of inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-hyper-CVD) for older patients with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia. Blood 130(25):(#2576), 2017.
35. Short NJ, Kantarjian HM, Garcia-Manero G, Borthakur G, Kadia T, Huang X, Daver N, DiNardo CD, Ferrajoli A, Wierda WG, Estrov Z, Benton CB, Bose P, Alvarado Y, Kornblau S, Ohanian M, Gaisor Y, Richie MA, Pierce S, Jabbour EJ, Cortes JE, Ravandi F. A randomized phase II trial of 5-day versus 10-day schedules of decitabine for older patients with previously untreated acute myeloid leukemia. Blood 130(25):(#2577), 2017.
36. Aboudalle I, Kantarjian HM, Burger JA, Estrov Z, Ohanian M, Jabbour EJ, Verstovsek S, Ravandi F, Borthakur G, Garcia-Manero G, Cortes JE. Efficacy and safety of generic imatinib after switching from innovator imatinib in patients treated fro chronic myeloid leukemia. Blood 130(25):(#2906), 2017.
37. Ashizawa AT, Ohanian M, Cortes JE. BP1001, a novel therapeutic for chronic myelogenous leukemia. Blood 128(22):(#4239), 2016.
38. Abaza Y, Kantarjian HM, Borthakur G, Garcia-Manero G, Daver N, Ravandi F, Verstovsek S, Burger JA, Estrov Z, Ohanian M, Lim M, Assi R, Jabbour EJ, Cortes JE. An open-label, phase I study of dasatinib in combination with decitabine in patients (pts) with accelerated or blastic phase chronic myeloid leukemia (CML). Blood 128(22):(#5433), 2016.
39. Short NJ, Garcia-Manero G, Naqvi K, Kornblau SM, Maiti A, Konopleva M, DiNardo CD, Takahashi K, Alvarado Y, Ohanian M, Estrov Z, Bose P, Andreeff M, Islam R, Dong X, Cortes JE, Kantarjian HM, Jabbour EJ. A phase II trial of omacetaxine mepesuccinate for patients with high-risk myelodysplastic syndrome after failure of hypomethylating agents. Blood 128(22):(#4328), 2016.
40. Ohanian M, Garcia-Manero G, Jabbour EJ, Daver N, Borthakur G, Kadia TM, Brandt M, Pierce. Combination of sorafenib and 5-azacytidine in older patients with untreated acute myeloid leukemia with FLT3-ITD mutation. Blood 128(22):(#1611), 2016.
41. Patel YB, Voit KN, Sasaki K, Ravandi F, Thomas DA, O'Brien SM, Borthakur G, Garcia-Manero G, Cortes JE, Konopleva M, Jain N, Ohanian M, Garris R, Jacob Jovitta, Kantarjian HM, Jabbour EJ. Methotrexate clearance in adult patients with B-precursor acute lymphoblastic leukemia treated with the mini-hyper-CVD regimen. Blood 128(22):(#5194), 2016.
42. Jain P, Kantarjian HM, Ravandi F, Jabbour E, Daver N, Pemmaraju N, DiNardo CD, Alvarado Y, Jain N, Borthakur G, Verstovsek S, Ferrajoli A, Ohanian M, Konopleva M, Naqvi K, Fitch T, Garcia-Manero G, Cortes JE, Estrov Z, Kadia TM. Cladribine combined with idarubicin and ara-C (CLIA) as a frontline and salvage treatment for young patients (</= 65 yrs) with acute myeloid leukemia. Blood 128(22):(#1639), 2016.
43. Boddu PC, Kantarjian HM, Garcia-Manero G, Verstovsek S, Ravandi F, Jabbour EJ, Takahashi K, Bhalla KN, Konopleva M, DiNardo CD, Ohanian M, Pemmaraju N, Jain N, Pierce S, Wierda WG, Cortes JE, Kadia TM. Characteristics and outcomes of older patients with secondary AML according to treatment approach. Blood 128(22):(#2788), 2016.
44. Montalban-Bravo G, Bose P, Alvarado Y, Daver N, Ravandi F, Borthakur G, Takahashi K, Andreeff M, Cortes JE, DiNardo CD, Jabbour E, Kadia TM, Kornblau SM, Ohanian M, Pierola AA, Huang X, Nogueras-Gonzalez GM, Bodden K, Littles K, Pierce S, Bueso-Ramos CE, Kantarjian HM, Garcia-Manero G. Initial results of a phase 2 study of guadecitabine (SGI-110), a novel subcutaneous (SC) hypomethylating agent, for patients with previously untreated intermediate-2 or high risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). Blood 128(22):(#346), 2016.
45. Khan M, Kantarjian HM, Garcia-Manero G, Borthakur G, Kadia TM, Huang X, Daver N, DiNardo CD, Ferrajoli A, Wierda WG, Estrov Z, Benton CB, Bose P, Alvarado Y, Kornblau SM, Ohanian M, Gasior Y, Richie MA, Pierce S, Jabbour EJ, Cortes JE, Ravandi F. Randomized phase II trial of two schedules of decitabine as frontline therapy in elderly patients with acute myeloid leukemia ineligible for standard cytotoxic induction regimens. Blood 128(22):(#1612), 2016.
46. Garcia-Manero G, Daver NG, Montalban-Bravo G, Jabbour EJ, DiNardo CD, Kornblau SM, Bose P, Alvarado Y, Ohanian M, Borthakur G, Cortes JE, Naqvi K, Pemmaraju N, Huang X, Nogueras-Gonzalez GM, Bueso-Ramos CE, Gasior Y, Bayer VR, Pierce S, Yang H, Colla S, Kantarjian HM EJ, DiNardo CD, Kornblau SM, Bose P, Alvarado Y, Ohanian M, Borthakur G, Cortes JE, Naqvi K, Pemmaraju N, Huang X, Nogueras-Gonzalez GM, Bueso-Ramos. A phase II study evaluating the combination of nivolumab (Nivo) or Ipilimumab (Ipi) with azacitidine in pts with previously treated or untreated myelodysplastic syndromes (MDS). Blood 128(22):(#344), 2016.
47. Ohanian M, Kantarjian HM, Borthakur G, Kadia TM, Konopleva M, Garcia-Manero G, Estrov Z, Ferrajoli A, Takahashi K, Jabbour EJ, Daver N, Kornblau SM, Wierda WG, Burger JA, Naqvi K, Benton CB, Bose P, Eckardt JR, Ravandi F, Cortes JE. Efficacy of a type I FLT3 inhibitor, crenolanib, with idarubicin and high-dose ara-C in multiply relapsed/refractory FLT3+ AML. Blood 128(22):(#2744), 2016.
48. Jain N, Basu S, Thompson PA, Ohanian M, Ferrajoli A, Pemmaraju N, Cortes JE, Estrov Z, Burger JA, Neelapu SS, Lopez W, Thakral B, Bueso-Ramos CE, Blando J, O'Brien SM, Kantarjian HM, Allison J, Keating M, Sharma P, Wierda WG. Nivolumab combined with ibrutinib for CLL and Richter transformation: a phase II trial. Blood 128(22):(#59), 2016.
49. Ragon BK, Daver N, Garcia-Manero G, Ohanian M, Ferrajoli A, Pemmaraju N, Kantarjian HM, Borthakur G. Fusion transcript reduction in core binding factor acute myeloid leukemia: maintenance strategy with hypomethylating agents. Blood 126(23):(#2604), 2015.
50. Vitale C, Ciccone M, Hinojosa C, Keating M, Pemmaraju N, O'Brien S, Wierda W, Thomas DA, Borthakur G, Ohanian M, Burger JA, Ferrajoli A. Front-line treatment with ofatumumab for older unfit patients with chronic lymphocytic leukemia. Blood 126(23):(#5292), 2015.
51. Tamamyan G, Borthakur G, Cortes JE, Ravandi F, Jabbour E, Daver N, Pemmaraju N, Ohanian M, Kolomansky A, Todisco G, Shi C, Pierce S, Peng SA, Konopleva M, Kantarjian HM, Kadia T. Prognostic score for adults with acute myeloid leukemia in first complete remission. Blood 126(23):(#3850), 2015.
52. Abaza Y, Kantarjian HM, Borthakur G, Daver N, Ravandi F, Chihara D, Verstovsek S, Burger JA, Estrov Z, Ohanian M, Jabbour E, Cortes JE. An open-label, phase I study of dasatinib in combination with decitabine in patients (pts) with accelerated or blastic phase chronic myeloid leukemia (CML). Blood 126(23):(#1589), 2015.
53. Ohanian M, Kantarjian HM, Ravandi F, Borthakur G, Garcia-Manero G, Andreeff M, Jabbour E, Konopleva M, Lim M, Pierce S, O'Brien S, Somer BG, Tari A, Wierda W, Verstovsek S, Cortes JE. Safety, pharmacokinetics, and efficacy of BP-100-1.01 (liposomal Grb-2 antisense oligonucleotide) in patients with refractory or relapsed acute myeloid leukemia (AML), Philadelphia chromosome positive chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome (MDS). Blood 126(23):(#3801), 2015.
54. Kadia T, Cortes JE, Jabbour EJ, Daver N, Pemmaraju N, Ravandi F, Jain N, Verstovsek S, DiNardo C, Alvarado Y, Ferrajoli A, Burger JA, Garcia-Manero G, Ohanian M, Konopleva M, Estrov Z, Wierda W, Brandt M, Fitch T, Borthakur G, Kantarjian HM. Phase II study of cladribine, idarubicin, and cytarabine (araC) in patients with acute myeloid leukemia (AML). Blood 126(23):(#2541), 2015.
55. Kadia T, Ravandi F, Daver N, Borthakur G, Cortes JE, Jabbour E, Kornblau SM, Verstovsek S, Wierda W, Burger JA, Estrov Z, DiNardo C, Dong XQ, Pemmaraju N, Ohanian M, Takahashi K, Hendrickson S, Kantarjian H, Garcia-Manero G. Single-center experience of immunosuppressive therapy with or without eltrombopag in patients with aplastic anemia. Blood 126(23):(#4779), 2015.
56. Ohanian M, Kantarjian H, Rozovski U, Loghavi S, Huh Y, Abruzzo L, Garcia-Manero G, Ravandi F, Borthakur G, Stingo F, Hu P, Nguyen M, Fox P, Medeiros L, Estrov Z, Bueso-Ramos C, Cortes J.. Clinical Significance of MYC Expression in Acute Myeloid Leukemia. J Clin Oncology 32(5s), 2014.
57. Ohanian M, Rozovski U, Kantarjian HM, Loghavi S, Huh YO, Abruzzo L, Garcia-Manero G, Ravandi F, Andreeff M, Kornblau SM, Borthakur G, Nguyen M, Stingo F, Hu P, Fox P, Medeiros LJ, Estrov Z, Bueso-Ramos CE, Cortes JE. MYC expression is prognostic in therapy related acute myeloid leukemia (AML) and AML with myelodysplastic syndrome (MDS)-related changes. Blood 124(21):(#5334), 2014.
58. Hu CW, Qutub AA, Qiu Y, Yoo SY, Zhang N, Daver NG, Ohanian M, Coombes K, Kornblau SM. Adhesion signaling states in AML. Blood 124(21):(#2386), 2014.
59. Ohanian M, Levis M, Faderl S, Garcia-Manero G, Jabbour E, Daver N, Dellasala S, Pierce S, Burger J, Cortes J, Kantarjian M, Ravandi F. Final report Of phase II study Of Sorafenib and 5-Azacytidine in patients with relapsed or untreated acute myeloid leukemia and FLT3-ITD mutation. Blood 122(21):(#3934), 2013.
60. Ohanian M, Kantarjian HM, Ravandi F, Borthakur G, Garcia-Manero G, Andreeff M, Jabbour E, Konopleva M, O'Brien S, Quintas-Cardama A, Somer BG, Tari A, Verstovsek S, Wierda WG, Cortes JEGarcia-Manero G, Andreeff M, Jabbour E, Konopleva M, O'Brien S, Quintas-Cardama A, Somer BG, Tari A, Verstovsek S, Wierda WG, Cortes JE. Safety, pharmacokinetics, and efficacy of BP-100-1.01 (liposomal Grb-2 antisense oligonucleotide) in patients with refractory or relapsed acute myeloid leukemia (AML), Philadelphia chromosome positive chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome (MDS). Blood 122(21):(#2679), 2013.
61. Rozovski U, Ohanian M, Favandi F, Garcia-Manero G, Faderl SH, Cortes JE, Pierce SR, Kantarjian H, Estrov Z. Incidence of and risk factors for acute myeloid leukemia involvement of the central nervous system. Blood 122(21):(#3883), 2013.
62. Ohanian M, Kantarjian H. Quintas-Cardama. The Clinical Impact of Time to Response in De Novo Accelerated Phase Chronic Myeloid Leukemia (CML-AP), Abstract 72, Presented at American Society of Hematology 2012, December 9,2012. J Clin Oncology, 2012.
63. Ohanian M, Alattar ML, Estrov Z, Quintas-Cardama A, Manning JT, Ravandi F, Abruzzo LV, Cortes JE, Pemmaraju N. Myeloid sarcoma of the orbit and ocular adnexae. Blood 120(21):(#1463), 2012.
64. Tran KM, Kantarjian HM, Kazmi SM, Quintas-Cardama A, Cortes JE, Estrov Z, Ohanian, Kadia TM, Borthakur G, Ravandi F, Pemmaraju N. Cytogenetic and molecular characterization of genitourinary extramedullary disease in acute myeloid leukemia. Blood 120(21):(#4326), 2012.
65. Ohanian M, Kantarjian HM, Quintas-Cardama A, Jabbour EJ, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Ferrajoli A, Kadia TM, O'Brien S, Cortes JE. The clinical impact of time to response in de novo accelerated phase chronic myeloid leukemia (CML-AP). Blood 120(21):(#72), 2012.
66. Alattar ML, Kantarjian HM, Cortes JE, Kadia TM, Borthakur G, Ohanian M, Ravandi F, Garcia-Manero G, Quintas-Cardamas A, Jabbour E, Daver N, Pierce SA, Brandt M, Faderl S, Pemmaraju N. Incidence and outcomes of a rare translocation t(3,5) in patients (pts) with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Blood 120(21):(#1456), 2012.
67. Ohanian M, Kantarjian HM, Quintas-Cardama A, O'Brien S, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Burton EM, Trinh LX, Ferrajoli A, Jabbour E, Kadia T, Cortes JE. Frontline tyrosine kinase inhibitors (TKI) as initial therapy for patients with chronic myeloid leukemia in accelerated phase (CML-AP). Blood 118(21):(#3779), 2011.
68. O'Brien S, Thomas DA, Ohanian M, Jorgenson JL, Kebriaei P, Jabbour E, Rytting ME, York S, Ravandi F, Kwari M, Faderl S, Rios MB, Cortes JE, Fayad L, Tarnai R, Wang SA, Champlin R, Advani AS, Kantarjian HM. Inotuzumab ozogamycin (IO), a CD22 monoclonal antibody conjugated to calecheamicin, is active in refractory-relapse acute lymphocytic leukemia (R-R ALL). Blood 118(21):(#875), 2011.
69. Ohanian M, Gasic S. Malignant Rigidity (A case of anti-amphyphysin antibody associated Stiff Person Syndrome). 16th Annual Southwest Texas ACP Associates’ Competition, Clinical Vignette Poster Competition Abstracts:16, 2009.
70. Ohanian M , Walters ET. Long term and short term effects of heat stress in the Aplysia: A behavioral and electrophysiological study, 2001 Summer Research Student Abstracts, page 28. Summer research fellowship at UT Houston Health Science Center, Department of Integrative Biology and Pharmacology;(support by NIH, NS35882), 2001.